Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome

Soon Jun Hong, Ji Young Park, Kyoung Ah Kim, Chul Min Ahn, Jae Suk Park, Yong Hyun Kim, Wan Joo Shim, Seong-Mi Park, Do-Sun Lim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and clinical events after coronary stenting was compared in patients with acute coronary syndrome (ACS). Methods and Results: Platelet aggregation was measured before clopidogrel administration and 4h, 24 h, 5 days, and 8 months later in 130 ACS patients. Stented patients were randomly assigned to atorvastatin either 10 mg (n=65) or 40 mg (n=65), and received an oral loading dose of 300 mg of clopidogrel followed by 75 mg/day for 8 months. Measurement of platelet aggregation was done by the turbimetric method. The mean % changes in inhibition of platelet aggregation were 35.5±8.3, 50.9±10.1, 38.3±8.3, 40.0±6.8 in the Atorvastatin 10 mg Group and 31.0±7.6, 43.7±9.8, 45.0±10.3, 43.5±7.8 (4 h, 24 h, 5 days, and 8 months, respectively, after 300 mg of clopidogrel pretreatment) in the Atorvastatin 40 mg Group with no significant differences between the 2 groups. Cardiovascular events showed no significant differences during the follow-up. Conclusions: Atorvastatin 10 mg or 40 mg co-administered with clopidogrel for 8 months did not affect the anti-platelet potency of clopidogrel and showed no significant differences in the clinical events in ACS patients.

Original languageEnglish
Pages (from-to)1111-1118
Number of pages8
JournalCirculation Journal
Volume73
Issue number6
DOIs
Publication statusPublished - 2009 Jun 1

Fingerprint

clopidogrel
Acute Coronary Syndrome
Platelet Aggregation
Atorvastatin Calcium
Blood Platelets

Keywords

  • Acute coronary syndrome
  • Atorvastatin
  • Clopidogrel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. / Hong, Soon Jun; Park, Ji Young; Kim, Kyoung Ah; Ahn, Chul Min; Park, Jae Suk; Kim, Yong Hyun; Shim, Wan Joo; Park, Seong-Mi; Lim, Do-Sun.

In: Circulation Journal, Vol. 73, No. 6, 01.06.2009, p. 1111-1118.

Research output: Contribution to journalArticle

@article{0a382f3be6f641e79b7e3970d4134a38,
title = "Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome",
abstract = "Background: The effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and clinical events after coronary stenting was compared in patients with acute coronary syndrome (ACS). Methods and Results: Platelet aggregation was measured before clopidogrel administration and 4h, 24 h, 5 days, and 8 months later in 130 ACS patients. Stented patients were randomly assigned to atorvastatin either 10 mg (n=65) or 40 mg (n=65), and received an oral loading dose of 300 mg of clopidogrel followed by 75 mg/day for 8 months. Measurement of platelet aggregation was done by the turbimetric method. The mean {\%} changes in inhibition of platelet aggregation were 35.5±8.3, 50.9±10.1, 38.3±8.3, 40.0±6.8 in the Atorvastatin 10 mg Group and 31.0±7.6, 43.7±9.8, 45.0±10.3, 43.5±7.8 (4 h, 24 h, 5 days, and 8 months, respectively, after 300 mg of clopidogrel pretreatment) in the Atorvastatin 40 mg Group with no significant differences between the 2 groups. Cardiovascular events showed no significant differences during the follow-up. Conclusions: Atorvastatin 10 mg or 40 mg co-administered with clopidogrel for 8 months did not affect the anti-platelet potency of clopidogrel and showed no significant differences in the clinical events in ACS patients.",
keywords = "Acute coronary syndrome, Atorvastatin, Clopidogrel",
author = "Hong, {Soon Jun} and Park, {Ji Young} and Kim, {Kyoung Ah} and Ahn, {Chul Min} and Park, {Jae Suk} and Kim, {Yong Hyun} and Shim, {Wan Joo} and Seong-Mi Park and Do-Sun Lim",
year = "2009",
month = "6",
day = "1",
doi = "10.1253/circj.CJ-08-1120",
language = "English",
volume = "73",
pages = "1111--1118",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome

AU - Hong, Soon Jun

AU - Park, Ji Young

AU - Kim, Kyoung Ah

AU - Ahn, Chul Min

AU - Park, Jae Suk

AU - Kim, Yong Hyun

AU - Shim, Wan Joo

AU - Park, Seong-Mi

AU - Lim, Do-Sun

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Background: The effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and clinical events after coronary stenting was compared in patients with acute coronary syndrome (ACS). Methods and Results: Platelet aggregation was measured before clopidogrel administration and 4h, 24 h, 5 days, and 8 months later in 130 ACS patients. Stented patients were randomly assigned to atorvastatin either 10 mg (n=65) or 40 mg (n=65), and received an oral loading dose of 300 mg of clopidogrel followed by 75 mg/day for 8 months. Measurement of platelet aggregation was done by the turbimetric method. The mean % changes in inhibition of platelet aggregation were 35.5±8.3, 50.9±10.1, 38.3±8.3, 40.0±6.8 in the Atorvastatin 10 mg Group and 31.0±7.6, 43.7±9.8, 45.0±10.3, 43.5±7.8 (4 h, 24 h, 5 days, and 8 months, respectively, after 300 mg of clopidogrel pretreatment) in the Atorvastatin 40 mg Group with no significant differences between the 2 groups. Cardiovascular events showed no significant differences during the follow-up. Conclusions: Atorvastatin 10 mg or 40 mg co-administered with clopidogrel for 8 months did not affect the anti-platelet potency of clopidogrel and showed no significant differences in the clinical events in ACS patients.

AB - Background: The effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and clinical events after coronary stenting was compared in patients with acute coronary syndrome (ACS). Methods and Results: Platelet aggregation was measured before clopidogrel administration and 4h, 24 h, 5 days, and 8 months later in 130 ACS patients. Stented patients were randomly assigned to atorvastatin either 10 mg (n=65) or 40 mg (n=65), and received an oral loading dose of 300 mg of clopidogrel followed by 75 mg/day for 8 months. Measurement of platelet aggregation was done by the turbimetric method. The mean % changes in inhibition of platelet aggregation were 35.5±8.3, 50.9±10.1, 38.3±8.3, 40.0±6.8 in the Atorvastatin 10 mg Group and 31.0±7.6, 43.7±9.8, 45.0±10.3, 43.5±7.8 (4 h, 24 h, 5 days, and 8 months, respectively, after 300 mg of clopidogrel pretreatment) in the Atorvastatin 40 mg Group with no significant differences between the 2 groups. Cardiovascular events showed no significant differences during the follow-up. Conclusions: Atorvastatin 10 mg or 40 mg co-administered with clopidogrel for 8 months did not affect the anti-platelet potency of clopidogrel and showed no significant differences in the clinical events in ACS patients.

KW - Acute coronary syndrome

KW - Atorvastatin

KW - Clopidogrel

UR - http://www.scopus.com/inward/record.url?scp=67649880262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649880262&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-08-1120

DO - 10.1253/circj.CJ-08-1120

M3 - Article

C2 - 19372620

AN - SCOPUS:67649880262

VL - 73

SP - 1111

EP - 1118

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -